[HTML][HTML] Inhibition of tissue factor pathway inhibitor by the aptamer BAX499 improves clotting of hemophilic blood and plasma
ME Gorczyca, SC Nair, B Jilma, S Priya, C Male… - Journal of Thrombosis …, 2012 - Elsevier
Background: Tissue factor pathway inhibitor (TFPI) is the major inhibitor of tissue factor‐
initiated coagulation, making it an interesting and novel therapeutic target in hemophilia
treatment. The aptamer BAX499 (formerly ARC19499) is designed to improve hemostasis by
specifically inhibiting TFPI. Objectives: The aim of the study was to examine the
concentration‐dependent augmentation of clotting by BAX499. Methods: Whole blood clot
formation was quantified by rotational thromboelastometry and thromboelastography, and …
initiated coagulation, making it an interesting and novel therapeutic target in hemophilia
treatment. The aptamer BAX499 (formerly ARC19499) is designed to improve hemostasis by
specifically inhibiting TFPI. Objectives: The aim of the study was to examine the
concentration‐dependent augmentation of clotting by BAX499. Methods: Whole blood clot
formation was quantified by rotational thromboelastometry and thromboelastography, and …